SRC: A Century of Science Brought to the Clinic by Alexey Aleshin, Richard S. Finn

Get full text

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. by Ferdows Ather, Habib Hamidi, Marlena S Fejzo, Stephen Letrent, Richard S Finn, Fairooz Kabbinavar, Christian Head, Steven G Wong

Get full text

Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review by David J Pinato, Kerigo Ndirangu, Richard S Finn, Zahra Ramji, Peter Galle, Catherine Ruth Mitchell, Gabrielle Sophie Redhead

Get full text

Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study by Richard S. Finn, Masatoshi Kudo, Gisoo Barnes, Tim Meyer, Frederic Boisserie, Ramil Abdrashitov, Yaxi Chen, Songzi Li, Andrew X. Zhu, Shukui Qin, Arndt Vogel

Get full text

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer by Joseph J. Zhao, Khi Yung Fong, Yiong Huak Chan, Jeremy Tey, Shaheenah Dawood, Soo Chin Lee, Richard S. Finn, Raghav Sundar, Joline S. J. Lim

Get full text

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer:... by Johannes Ettl, Seock-Ah Im, Jungsil Ro, Norikazu Masuda, Marco Colleoni, Patrick Schnell, Eustratios Bananis, Dongrui R. Lu, Massimo Cristofanilli, Hope S. Rugo, Richard S. Finn

Get full text

Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave1... by Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel

Get full text

IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma—An Explor... by Masatoshi Kudo, Richard S. Finn, Peter R. Galle, Andrew X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni

Get full text

Characterization of Tumor Responses in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib in the Phase 3 Randomized Trial, REFLECT by Richard S. Finn, Shukui Qin, Fabio Piscaglia, Thomas R Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo

Get full text

Atezolizumab in combination with bevacizumab for the management of patients with hepatocellular cancer in the first-line setting: systematic literature review and meta-analysis by Arndt Vogel, Richard S. Finn, Marie-Hélène Blanchet Zumofen, Carolina Heuser, Javier Sanchez Alvarez, Michael Leibfried, Catherine R. Mitchell, Sarah Batson, Gabrielle Redhead, Vincent E. Gaillard, Masatoshi Kudo

Get full text

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer by Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele

Get full text

Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma by Saleh A Alqahtani, Faisal M Sanai, Ashwaq Alolayan, Faisal Abaalkhail, Hamad Alsuhaibani, Mazen Hassanain, Waleed Alhazzani, Abdullah Alsuhaibani, Abdullah Algarni, Alejandro Forner, Richard S Finn, Waleed K Al-hamoudi

Get full text

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab by Chiun Hsu, Michel Ducreux, Andrew X. Zhu, Shukui Qin, Masafumi Ikeda, Tae-You Kim, Peter R. Galle, Richard S. Finn, Ethan Chen, Ning Ma, Youyou Hu, Lindong Li, Ann-Lii Cheng

Get full text

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus... by Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, Ryosuke Take, Kyoko Yamada, Takashi Asakawa, Yuki Nakagawa, Masafumi Ikeda

Get full text

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative a... by Hope S. Rugo, Seock-Ah Im, Anil A. Joy, Yaroslav Shparyk, Janice M. Walshe, Bethany Sleckman, Sherene Loi, Kathy Puyana Theall, Sindy Kim, Xin Huang, Eustratios Bananis, Reshma Mahtani, Richard S. Finn, Véronique Diéras

Get full text

Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma by Kiri A. Sandler, MD, Darlene Veruttipong, MPH, Vatche G. Agopian, MD, Richard S. Finn, MD, Johnny C. Hong, MD, Fady M. Kaldas, MD, Saeed Sadeghi, MD, Ronald W. Busuttil, MD PhD, Percy Lee, MD

Get full text

A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116 by Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari D. Baron, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, Satoshi Nagao, Kenichi Saito, Kalgi Mody, Zahra Ramji, Leonid Dubrovsky, Josep M. Llovet

Get full text

Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysisResearch in context by Anand V. Kulkarni, Harshvardhan Tevethia, Karan Kumar, Madhumita Premkumar, Mark D. Muttaiah, Atsushi Hiraoka, Takeshi Hatanaka, Toshifumi Tada, Takashi Kumada, Satoru Kakizaki, Arndt Vogel, Richard S. Finn, Padaki Nagaraja Rao, Anjana Pillai, Duvvur Nageshwar Reddy, Amit G. Singal

Get full text

ALBI score and outcomes in patients with hepatocellular carcinoma: analysis of the randomized controlled trial KEYNOTE-240 by Arndt Vogel, Philippe Merle, Chris Verslype, Richard S. Finn, Andrew X. Zhu, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Baek-Yeol Ryoo, Jennifer Knox, Bruno Daniele, Shukui Qin, Ziwen Wei, Yanna Miteva, Usha Malhotra, Abby B. Siegel, Masatoshi Kudo

Get full text

Hepatocellular Carcinoma–Circulating Tumor Cells Expressing PD‐L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors by Paul Winograd, Shuang Hou, Colin M. Court, Yi‐Te Lee, Pin‐Jung Chen, Yazhen Zhu, Saeed Sadeghi, Richard S. Finn, Pai‐Chi Teng, Jasmin J. Wang, Zhicheng Zhang, Hongtao Liu, Ronald W. Busuttil, James S Tomlinson, Hsian‐Rong Tseng, Vatche G. Agopian

Get full text